Instead of solely neutralizing CD39 ecto-enzymatic activities, glycoengineered Afuc αCD39 IgG2c mAbs selectively deplete CD39hi TAECs and TAMs, abrogate angiogenesis, and decrease overall CD39 levels in the tumor. The gene discussed is ENTPD1; the disease is neoplasm.